Matches in SemOpenAlex for { <https://semopenalex.org/work/W2541083871> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2541083871 endingPage "A731" @default.
- W2541083871 startingPage "A731" @default.
- W2541083871 abstract "To review the evidence, submitted to the National Institute of Health and Care Excellence (NICE) by Celgene, on the clinical and cost-effectiveness of azacitidine for the treatment of acute myeloid leukaemia in adults with >30% bone marrow blasts who are not eligible for hematopoietic stem cell transplantation, as part of the NICE Single Technology Appraisal process. The company’s analysis was based on data from a randomized controlled trial, AZA-AML-001. The trial was conducted to determine the efficacy and safety of azacitidine against a conventional care regimen (CCR) comprised of three individual comparators: intensive chemotherapy followed by best supportive care (BSC) upon disease relapse or progression, non-intensive chemotherapy followed by BSC, and BSC alone. The primary trial end point, overall survival, was affected by treatment switching in both arms. The company’s economic evaluation was based on a partitioned survival model with four states: Remission, Non-remission, Relapse/Progressive disease and Death. We critically appraised the company’s submission; assessed the replicability and internal validity of their analysis using individual-patient data from AZA-AML-001; and examined the effect on incremental cost-effectiveness ratio (ICER) of crossover, and of altering model assumptions to reflect current UK practice. In the company’s analysis, the base-case ICER of azacitidine vs. CCR was £20,648 per quality-adjusted life-year (QALY) gained; in their probabilistic sensitivity analysis, the ICER was £17,423. After our amendments to Celgene’s model, the respective ICERs were £273,308 and £277,123 per QALY. In all our exploratory analyses, the ICER exceeded NICE’s threshold range of £20,000 to £30,000 per QALY gained. The major drivers of the increase in the ICER were model corrections related to healthcare resource use, and calibration of the number of treatment cycles (for consistency with AZA-AML-001). After considering these analyses and statements from patient and clinical experts, the NICE Appraisal Committee did not recommend azacitidine for this indication." @default.
- W2541083871 created "2016-11-04" @default.
- W2541083871 creator A5014194484 @default.
- W2541083871 creator A5018526977 @default.
- W2541083871 creator A5027344461 @default.
- W2541083871 creator A5054440572 @default.
- W2541083871 creator A5065378097 @default.
- W2541083871 creator A5069352430 @default.
- W2541083871 creator A5086010333 @default.
- W2541083871 date "2016-11-01" @default.
- W2541083871 modified "2023-09-29" @default.
- W2541083871 title "Azacitidine for Treating Acute Myeloid Leukaemia: A Nice Single Technology Appraisal" @default.
- W2541083871 doi "https://doi.org/10.1016/j.jval.2016.09.2201" @default.
- W2541083871 hasPublicationYear "2016" @default.
- W2541083871 type Work @default.
- W2541083871 sameAs 2541083871 @default.
- W2541083871 citedByCount "0" @default.
- W2541083871 crossrefType "journal-article" @default.
- W2541083871 hasAuthorship W2541083871A5014194484 @default.
- W2541083871 hasAuthorship W2541083871A5018526977 @default.
- W2541083871 hasAuthorship W2541083871A5027344461 @default.
- W2541083871 hasAuthorship W2541083871A5054440572 @default.
- W2541083871 hasAuthorship W2541083871A5065378097 @default.
- W2541083871 hasAuthorship W2541083871A5069352430 @default.
- W2541083871 hasAuthorship W2541083871A5086010333 @default.
- W2541083871 hasBestOaLocation W25410838711 @default.
- W2541083871 hasConcept C104317684 @default.
- W2541083871 hasConcept C126322002 @default.
- W2541083871 hasConcept C143998085 @default.
- W2541083871 hasConcept C150194340 @default.
- W2541083871 hasConcept C177713679 @default.
- W2541083871 hasConcept C185592680 @default.
- W2541083871 hasConcept C190727270 @default.
- W2541083871 hasConcept C199360897 @default.
- W2541083871 hasConcept C2776239401 @default.
- W2541083871 hasConcept C2779256446 @default.
- W2541083871 hasConcept C2781413609 @default.
- W2541083871 hasConcept C2911091166 @default.
- W2541083871 hasConcept C41008148 @default.
- W2541083871 hasConcept C535046627 @default.
- W2541083871 hasConcept C55493867 @default.
- W2541083871 hasConcept C71924100 @default.
- W2541083871 hasConceptScore W2541083871C104317684 @default.
- W2541083871 hasConceptScore W2541083871C126322002 @default.
- W2541083871 hasConceptScore W2541083871C143998085 @default.
- W2541083871 hasConceptScore W2541083871C150194340 @default.
- W2541083871 hasConceptScore W2541083871C177713679 @default.
- W2541083871 hasConceptScore W2541083871C185592680 @default.
- W2541083871 hasConceptScore W2541083871C190727270 @default.
- W2541083871 hasConceptScore W2541083871C199360897 @default.
- W2541083871 hasConceptScore W2541083871C2776239401 @default.
- W2541083871 hasConceptScore W2541083871C2779256446 @default.
- W2541083871 hasConceptScore W2541083871C2781413609 @default.
- W2541083871 hasConceptScore W2541083871C2911091166 @default.
- W2541083871 hasConceptScore W2541083871C41008148 @default.
- W2541083871 hasConceptScore W2541083871C535046627 @default.
- W2541083871 hasConceptScore W2541083871C55493867 @default.
- W2541083871 hasConceptScore W2541083871C71924100 @default.
- W2541083871 hasIssue "7" @default.
- W2541083871 hasLocation W25410838711 @default.
- W2541083871 hasLocation W25410838712 @default.
- W2541083871 hasOpenAccess W2541083871 @default.
- W2541083871 hasPrimaryLocation W25410838711 @default.
- W2541083871 hasRelatedWork W182989684 @default.
- W2541083871 hasRelatedWork W1986713097 @default.
- W2541083871 hasRelatedWork W2065856818 @default.
- W2541083871 hasRelatedWork W2089045987 @default.
- W2541083871 hasRelatedWork W29179590 @default.
- W2541083871 hasRelatedWork W3118107215 @default.
- W2541083871 hasRelatedWork W4231022123 @default.
- W2541083871 hasRelatedWork W4242643752 @default.
- W2541083871 hasRelatedWork W4254819107 @default.
- W2541083871 hasRelatedWork W4312873564 @default.
- W2541083871 hasVolume "19" @default.
- W2541083871 isParatext "false" @default.
- W2541083871 isRetracted "false" @default.
- W2541083871 magId "2541083871" @default.
- W2541083871 workType "article" @default.